Evidence map›Paper›PMID 34572021›Full record

ArticleCells2021

A New Approach for Prostate Cancer Diagnosis by miRNA Profiling of Prostate-Derived Plasma Small Extracellular Vesicles.

Lidia Zabegina, Inga Nazarova, Nadezhda Nikiforova, Maria Slyusarenko, Elena Sidina, Margarita Knyazeva, Evgenia Tsyrlina, Sergey Novikov, Sergey Reva, Anastasia Malek

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Exosomal RNAs: Novel Potential Biomarkers for Diseases-A Review.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lidia ZabeginaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.
Inga NazarovaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.ORCID 0000-0002-6812-3088
Nadezhda NikiforovaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.ORCID 0000-0001-7464-4237
Maria SlyusarenkoDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.ORCID 0000-0002-3677-1558
Elena SidinaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.
Margarita KnyazevaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.ORCID 0000-0002-2079-5061
Evgenia TsyrlinaDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.
Sergey NovikovDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.
Sergey RevaDepartment of Andrology and Urology, Research Center of Urology, Pavlov First Saint Petersburg State Medical University, 197022 St. Petersburg, Russia.
Anastasia MalekDepartment of Radiotherapy, Subcellular Technology Laboratory, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia.ORCID 0000-0001-5334-7292
Nanosystem (Russia) · RUFirst Pavlov State Medical University of St. Petersburg · RU

Funding

Ministry of Health of the Russian Federation AAAA-A18-118032890186-5
6 · The paper itself

Abstract

Vesicular miRNA has emerged as a promising marker for various types of cancer, including prostate cancer (PC). In the advanced stage of PC, the cancer-cell-derived small extracellular vesicles (SEVs) may constitute a significant portion of circulating vesicles and may mediate a detectable change in the plasma vesicular miRNA profile. However, SEVs secreted by small tumor in the prostate gland constitute a tiny fraction of circulating vesicles and cause undetectable miRNA pattern changes. Thus, the isolation and miRNA profiling of a specific prostate-derived fraction of SEVs can improve the diagnostic potency of the methods based on vesicular miRNA analysis. Prostate-specific membrane antigen (PSMA) was selected as a marker of prostate-derived SEVs. Super-paramagnetic beads (SPMBs) were functionalized by PSMA-binding DNA aptamer (PSMA-Apt) via a click reaction. The efficacy of SPMB-PSMA-Apt complex formation and PSMA(+)SEVs capture were assayed by flow cytometry. miRNA was isolated from the total population of SEVs and PSMA(+)SEVs of PC patients (n = 55) and healthy donors (n = 30). Four PC-related miRNAs (miR-145, miR-451a, miR-143, and miR-221) were assayed by RT-PCR. The click chemistry allowed fixing DNA aptamers onto the surface of SPMB with an efficacy of up to 89.9%. The developed method more effectively isolates PSMA(+)SEVs than relevant antibody-based technology. The analysis of PC-related miRNA in the fraction of PSMA(+)SEVs was more sensitive and revealed distinct diagnostic potency (AUC: miR-145, 0.76; miR-221, 0.7; miR-451a, 0.65; and miR-141, 0.64) than analysis of the total SEV population. Thus, isolation of prostate-specific SEVs followed by analysis of vesicular miRNA might be a promising PC diagnosis method.

Indexed as

AgedAptamers, NucleotideBiomarkers, TumorExtracellular VesiclesHumansMaleMicroRNAsMiddle AgedProstateProstatic NeoplasmsAptamers, NucleotideBiomarkers, TumorMicroRNAsclick chemistrydiagnosticsmicroRNAmiRNAprostate cancerPSMAPSMA(+)SEVsSEVssmall extracellular vesicles

Identifiers

PMID34572021
PMCPMC8467918
OpenAlexW3197692755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.